Showing results (1-10 of 95) with videos related to
Sort By:
Pageof 10
Seminars in Thrombosis and Hemostasis|August 10, 1999
Pharmacokinetics of clopidogrelH Caplain, F Donat, C Gaud, et al.Seminars in Thrombosis and Hemostasis|August 10, 1999
Clopidogrel does not affect the pharmacokinetics of theophyllineH Caplain, J J Thebault, J NecciariThrombosis and Haemostasis|March 11, 1998
Pharmacodynamics and tolerance of two nadroparin formulations (10,250 and 20,500 anti Xa IU x ml(-1)) delivered for 10 days at therapeutic doseB Boneu, C Navarro, J P Cambus, et al.Journal of Cardiovascular Pharmacology|January 1, 1990
Development and pharmacokinetics of a new sustained-release formulation of diltiazemJ F Thiercelin, J Necciari, H Caplain, et al.Cerebrovascular Diseases (Basel, Switzerland)|February 11, 2005
Enhanced antiplatelet effects of clopidogrel plus acetylsalicylic acid compared with acetylsalicylic acid alone or combined with extended-release dipyridamole in healthy volunteersH CaplainSeminars in Thrombosis and Hemostasis|August 10, 1999
Long-term activity of clopidogrel: a three-month appraisal in healthy volunteersH Caplain, R CariouThrombosis and Haemostasis|July 10, 1998
Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin)P Mismetti, S Laporte-Simitsidis, C Navarro, et al.Seminars in Thrombosis and Hemostasis|August 10, 1999
Prolonged heparin administration during clopidogrel treatment in healthy subjectsH Caplain, G D'Honneur, R CariouArchives of Neurology|September 1, 1981
Septo-optic dysplasia in an infant of a diabetic motherJ F DonatEuropean Journal of Drug Metabolism and Pharmacokinetics|July 1, 1991
A single blind normal volunteer bioavailability study of a new microencapsulated potassium chloride tablet compared with two reference potassium formulationsH Caplain, R Dahan, R Pamphile, et al.Pageof 10